Sign In
Buy ABBV
$250.88
-6.74 (-2.61%)
At Close: Jul 31, 2026
Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey ® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for t
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
07:55am, Tuesday, 23'rd Jun 2026
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology d
G50 Corp strikes high-grade gold at first White Caps core hole in Nevada
07:32am, Tuesday, 23'rd Jun 2026
G50 Corp Ltd (ASX:G50, OTCQB:GFYTF) has delivered a strong first result from its 2026 core drilling program at the White Caps Gold Project in Nevada,...
3 Monster Stocks to Hold for the Next 10 Years
06:05am, Tuesday, 23'rd Jun 2026
These players sell market-leading products and are tackling growth industries. Holding for several years, rather than a short period, allows investors to fully benefit from each company's story.
MAVIRET ® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in a
Empire Metals to host investor presentation on Pitfield progress
04:08am, Tuesday, 23'rd Jun 2026
Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF), the AIM-quoted and OTCQX-traded exploration and development company, will present to investors on 30 June....
AbbVie Announces European Commission Approval of SKYRIZIÂ (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaqu
Metals One builds 5.57% stake in newly listed Talon Resources
03:25am, Tuesday, 23'rd Jun 2026
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has built a 5.57% stake in Talon Resources. The holding was...
SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-
Why AbbVie Stock Jumped Today
10:58pm, Monday, 22'nd Jun 2026
AbbVie is making smart moves to bolster its lucrative immunology business. The healthcare leader is working to diversify its sales and profits.
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
06:36pm, Monday, 22'nd Jun 2026
The deal gives the company a strong asset in zumilokibart, Apogee's very promising investigational drug. Apogee stockholders are to be paid $135.11 per share in the all-cash transaction.
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
05:54pm, Monday, 22'nd Jun 2026
On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.
AbbVie Inc (ABBV) Shares Surge 6.2% -- What GF Score of 82 Tells Investors
05:11pm, Monday, 22'nd Jun 2026
On June 22, 2026, AbbVie Inc (ABBV) shares rose 6.2% to a current price of $230.01. This increase comes amidst a 52-week trading range of $181.73 to $244.81, in
AbbVie Inc. (ABBV) M&A Call Transcript
05:02pm, Monday, 22'nd Jun 2026
AbbVie Inc. (ABBV) M&A Call Transcript
Nasdaq slides but Dow closes higher as investors ditch megacap tech
12:18pm, Monday, 22'nd Jun 2026
4:15pm: Big Tech selloff US stocks finished mixed on Monday as steep losses in some of the market's biggest technology names outweighed gains across much of...
